Posted on

FDA Issues Emergency Use Authorization for Johnson & Johnson Sigle Dose COVID Vaccine

c9215d4f 47bf 4fbe ad5a 570047c8daf0

the staff of the Ridgewood blog

Washington DC, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.

Continue reading FDA Issues Emergency Use Authorization for Johnson & Johnson Sigle Dose COVID Vaccine

Posted on

Johnson & Johnson’s Single Dose COVID-19 Vaccine 66% effective overall in preventing moderate to severe COVID-19

Vaccine in vial with syringe1

the staff of the Ridgewood blog

NEW BRUNSWICK NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19.

Continue reading Johnson & Johnson’s Single Dose COVID-19 Vaccine 66% effective overall in preventing moderate to severe COVID-19